X hits on this document

Word document

ПРОТОКОЛ ВЕДЕНИЯ БОЛЬНЫХ - page 219 / 220

1195 views

0 shares

0 downloads

0 comments

219 / 220

50.

Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S, for the 053 Study Group. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. Neurology 1999; 53: 364-370.  

51.

Kumar R, Lozano AM, Kim YJ, et al: Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology 51:850, 1998

52.

Lieberman A, Ranhosky A, Korts D: Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study. Neurology 49:162, 1997

53.

Lees A. J., Katzenschlager R., Head J. et al.. Ten-year follow-up of three different initial treatments in de-novo PD // Neurology, 2001. – V.57. -P. 154-161.

54.

Litvan I., Bhatia K., Burn D.J. et al. SIC Task force appraisal of clinical diagnostic criteria for parkinsonian disorders.//Mov. Disord., 2003. — V. 18. – P. 467-486.

55.

Marsden C.D. Parkinson's disease//J. Neurol. Neurosurg. Psychiatry, 1994.-V.57.-P.672-681.

56.

Marsden C.D., Fahn S. Problems in Parkinson's disease and other akinetic-rigid syndromes // In: C.D.Marsden, S.Fahn (eds). Movement disorders 3. Cambrridge, Butterworth Heinemann, 1994. -P.117-123

57.

Mathias C.J., Kimber J.R. Treatment of postural hypotension// J Neurol. Neurosurg. Psychiatry, 1998. -V.65. -P. 285-289.

58.

McKeith I.G., Galasko D., Kosaka K. et al. Consensus guidlines for the clinical and pathologic diagnosis of dementia with Lewy bodies //Neurology, 1996. -V.47. -P.113-1124.

59.

Miyasaki J.M., Martin W., Suchowersky O. et al. Practice parameter: Initiation of treatment for Parkinson disease: An evidence-based review. Neurology. 2002; 58:11-17.

60.

Muller J, Wenning GK, Jellinger K, et al. Progression of Hoehn and Yahr stages in parkinsonian disorders: a clinicopathologic study. //Neurology, 2000.-V.55.-P.888-891.

61.

Münchau A., Bhatia K.P. Pharmacological treatment of Parkinson's disease. Postgrad. Med. J. 2000; 76(October):602-610

62.

Nutt JG, Carter JH, Van Houten L, et al. Short- and long-duration responses to levodopa during the first year of levodopa therapy. //Ann. Neurol., 1997.-V.42.-P.349-355.

63.

Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. //Ann. Neurol., 1996.-V.39.-P.561-573.

64.

Oertel W. Н., Quinn N. P. Parkinsonism // Neurological Disor­ders: Course and Treatment. — New York, 2002. — P. 715— 772.

65.

Olanow  C.W., Stocchi F. Why delaying levodopa is a good treatment strategy in early Parkinson’s  Disease. Eur. J. Neurol., 2000;7 suppl. 1: S.3-8

Document info
Document views1195
Page views1195
Page last viewedFri Dec 09 12:14:05 UTC 2016
Pages220
Paragraphs3090
Words41635

Comments